Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy

Alexander Yakobson, Wafeek Alguayn, Walid Shalata, Daniel Levin, Tawfeek A. Kian, Amir Korngreen, Rachel Gibbs, Mahmuod A. Salah, Benzion Samueli, Konstantin Lavrenkov, Laila C. Roisman, Yulia Dudnik, Nir Peled, Yael Refaely, Waleed Kian

    Research output: Contribution to journalArticlepeer-review

    2 Scopus citations


    Epithelioid hemangioma (EH) and epithelioid hemangioendothelioma (EHE) are both rare vascular tumors. EH tumors are often benign while EHE tumors have moderate malignant potential. Here, we present three unique cases at Soroka Medical Center, two featuring EH of the bone and one presenting EHE of the mediastinum. Each case demonstrates distinct treatment challenges due to the rarity of both diseases and lack of established guidelines. We propose three treatment approaches including pazopanib for salvage therapy of EH of the bone and minimally invasive surgical resection which in these cases lead to complete symptom relief and tumor stabilization upheld over time with close follow-up.

    Original languageEnglish
    Pages (from-to)309-317
    Number of pages9
    JournalCase Reports in Oncology
    Issue number1
    StatePublished - 1 Jan 2021


    • Epithelioid hemangioendothelioma
    • Pazopanib
    • Rib epithelioid hemangioma

    ASJC Scopus subject areas

    • Oncology


    Dive into the research topics of 'Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy'. Together they form a unique fingerprint.

    Cite this